SGFY
Signify Health, Inc. [SGFY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SGFY Stock Summary
In the News
SGFY Financial details
Company Rating
Buy
Market Cap
8.93B
Income
-130.4M
Revenue
805.5M
Book val./share
3.56
Cash/share
2.64
Dividend
-
Dividend %
-
Employees
2.1K
Optionable
No
Shortable
Yes
Earnings
01 Aug 2023
P/E
-41.22
Forward P/E
-
PEG
0.3
P/S
11.09
P/B
8.57
P/C
-
P/FCF
128.17
Quick Ratio
1.32
Current Ratio
1.62
Debt / Equity
0.58
LT Debt / Equity
0.44
-
-
EPS (TTM)
-0.73
EPS next Y
-
EPS next Q
-
EPS this Y
-1386.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
32.68%
Revenue last 5Y
18.97%
Revenue Q/Q
45.21%
EPS Q/Q
-368.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.07%
Inst Trans
0%
ROA
-7%
ROE
-16%
ROC
0.08%
Gross Margin
45%
Oper. Margin
12%
Profit Margin
-16%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.7-30.5
52W High
-
52W Low
-
RSI
-
Rel Volume
3.63
Avg Volume
2.65M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.362377
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
SGFY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.06 | 3.05 | 3.68 | 4.49 | 4.57 | |
| Net income per share | -0.18 | -0.17 | -0.09 | 0.06 | -0.74 | |
| Operating cash flow per share | 0.22 | 0.25 | 0.26 | 0.75 | 0.56 | |
| Free cash flow per share | 0.14 | 0.1 | 0.06 | 0.59 | 0.4 | |
| Cash per share | 0.12 | 0.17 | 0.44 | 3.94 | 2.64 | |
| Book value per share | 1.73 | 5.83 | 5.39 | 6.53 | 3.56 | |
| Tangible book value per share | -1.49 | -0.91 | -1.26 | 2.56 | 0.18 | |
| Share holders equity per share | 1.73 | 5.83 | 5.39 | 6.53 | 3.56 | |
| Interest debt per share | 1.65 | 1.76 | 2.55 | 2.09 | 2.17 | |
| Market cap | 5.18B | 5.18B | 5.23B | 2.45B | 5.05B | |
| Enterprise value | 5.41B | 5.42B | 5.56B | 2.11B | 4.95B | |
| P/E ratio | -179.38 | -181.89 | -360.95 | 247.15 | -38.75 | |
| Price to sales ratio | 15.34 | 10.33 | 8.57 | 3.16 | 6.27 | |
| POCF ratio | 145.62 | 124.32 | 120.32 | 18.84 | 51.56 | |
| PFCF ratio | 230.4 | 320 | 556.78 | 24.15 | 72.49 | |
| P/B Ratio | 18.25 | 5.41 | 5.85 | 2.18 | 8.05 | |
| PTB ratio | 18.25 | 5.41 | 5.85 | 2.18 | 8.05 | |
| EV to sales | 16.02 | 10.81 | 9.11 | 2.72 | 6.14 | |
| Enterprise value over EBITDA | 151.63 | 61.91 | 64.01 | 15.89 | -178.65 | |
| EV to operating cash flow | 152.05 | 130.06 | 127.87 | 16.22 | 50.5 | |
| EV to free cash flow | 240.58 | 334.8 | 591.75 | 20.8 | 71 | |
| Earnings yield | -0.01 | -0.01 | 0 | 0 | -0.03 | |
| Free cash flow yield | 0 | 0 | 0 | 0.04 | 0.01 | |
| Debt to equity | 0.88 | 0.28 | 0.45 | 0.3 | 0.58 | |
| Debt to assets | 0.41 | 0.19 | 0.26 | 0.16 | 0.21 | |
| Net debt to EBITDA | 6.42 | 2.74 | 3.78 | -2.56 | 3.75 | |
| Current ratio | 2.1 | 2.15 | 2.05 | 5.46 | 1.62 | |
| Interest coverage | -0.34 | 1.02 | 1.11 | 2.85 | 5.29 | |
| Income quality | -1.23 | -1.46 | -3 | 13.12 | -0.75 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.63 | -0.79 | -0.57 | 0 | 0 | |
| Sales general and administrative to revenue | 0.64 | 0.49 | 0.5 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.88 | 0.8 | 0.72 | 0.49 | 0.45 | |
| Capex to operating cash flow | -0.37 | -0.61 | -0.78 | -0.22 | -0.29 | |
| Capex to revenue | -0.04 | -0.05 | -0.06 | -0.04 | -0.04 | |
| Capex to depreciation | -0.3 | -0.39 | -0.55 | -0.4 | -0.48 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.05 | |
| Graham number | 2.62 | 4.77 | 3.26 | 2.91 | 7.7 | |
| ROIC | -0.01 | 0.02 | 0.02 | 0.03 | 0.1 | |
| Return on tangible assets | -0.39 | -0.1 | -0.03 | 0.01 | -0.14 | |
| Graham Net | -1.62 | -1.54 | -2.09 | 1.33 | -1.48 | |
| Working capital | 33.9M | 140.9M | 199.6M | 817.5M | 306.1M | |
| Tangible asset value | -244.5M | -149.7M | -209.6M | 440.5M | 32.4M | |
| Net current asset value | -253.1M | -171.3M | -239.1M | 366.3M | -127M | |
| Invested capital | 0.88 | 0.28 | 0.45 | 0.3 | 0.58 | |
| Average receivables | 0 | 123.65M | 252.4M | 299.95M | 242.25M | |
| Average payables | 0 | 2.55M | 2.1M | 3.15M | 7.15M | |
| Average inventory | 0 | 0 | -13.9M | -56.05M | 17.9M | |
| Days sales outstanding | 44.18 | 150.13 | 178.38 | 142.29 | 82.92 | |
| Days payables outstanding | 0 | 5.17 | 0.83 | 5.19 | 7.21 | |
| Days of inventory on hand | 0 | 0 | -33.08 | -78.19 | 99.54 | |
| Receivables turnover | 8.26 | 2.43 | 2.05 | 2.57 | 4.4 | |
| Payables turnover | 0 | 70.63 | 438.14 | 70.27 | 50.62 | |
| Inventory turnover | 0 | 0 | -11.03 | -4.67 | 3.67 | |
| ROE | -0.1 | -0.03 | -0.02 | 0.01 | -0.21 | |
| Capex per share | -0.08 | -0.16 | -0.21 | -0.17 | -0.16 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.06 | 1.25 | 1.4 | 0.79 | 1.15 | |
| Net income per share | 0.19 | -0.09 | -2.78 | -1.27 | 3.41 | |
| Operating cash flow per share | -0.47 | -0.19 | -0.02 | 0.33 | 0.42 | |
| Free cash flow per share | -0.35 | -0.24 | -0.07 | 0.29 | 0.41 | |
| Cash per share | 3.98 | 2.61 | 2.49 | 2.6 | 2.64 | |
| Book value per share | 6.59 | 6.78 | 4.57 | 3.71 | 3.56 | |
| Tangible book value per share | 0.42 | 1.21 | 1.5 | 0.36 | 0.18 | |
| Share holders equity per share | 6.59 | 6.78 | 4.57 | 3.71 | 3.56 | |
| Interest debt per share | 2.01 | 2.13 | 2.1 | 2.09 | 2.09 | |
| Market cap | 2.43B | 3.14B | 2.43B | 5.17B | 5.05B | |
| Enterprise value | 2.09B | 3.05B | 2.36B | 5.07B | 4.95B | |
| P/E ratio | 18.71 | -48.09 | -1.24 | -5.75 | 2.1 | |
| Price to sales ratio | 13.37 | 14.48 | 9.88 | 36.99 | 24.89 | |
| POCF ratio | -30.35 | -97.08 | -760.51 | 87.96 | 67.64 | |
| PFCF ratio | -41.04 | -76.85 | -190.13 | 100.62 | 70.27 | |
| P/B Ratio | 2.16 | 2.68 | 3.02 | 7.85 | 8.05 | |
| PTB ratio | 2.16 | 2.68 | 3.02 | 7.85 | 8.05 | |
| EV to sales | 11.5 | 14.08 | 9.59 | 36.3 | 24.38 | |
| Enterprise value over EBITDA | 38.7 | 662.51 | 37.28 | -23 | 39.34 | |
| EV to operating cash flow | -26.1 | -94.35 | -737.54 | 86.3 | 66.25 | |
| EV to free cash flow | -35.29 | -74.69 | -184.39 | 98.72 | 68.83 | |
| Earnings yield | 0.01 | -0.01 | -0.2 | -0.04 | 0.12 | |
| Free cash flow yield | -0.02 | -0.01 | -0.01 | 0.01 | 0.01 | |
| Debt to equity | 0.3 | 0.31 | 0.45 | 0.55 | 0.58 | |
| Debt to assets | 0.19 | 0.16 | 0.21 | 0.21 | 0.21 | |
| Net debt to EBITDA | -6.3 | -19.15 | -1.16 | 0.44 | -0.83 | |
| Current ratio | 5.46 | 4.82 | 5.23 | 1.9 | 1.62 | |
| Interest coverage | 8.29 | -3.78 | 9 | -9.47 | 20.93 | |
| Income quality | -3.52 | 1.98 | 0.01 | -0.26 | 0.12 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.54 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.6 | 0.59 | 0.46 | 0.46 | 0.45 | |
| Capex to operating cash flow | -0.26 | 0.26 | 3 | -0.13 | -0.04 | |
| Capex to revenue | 0.11 | -0.04 | -0.04 | -0.05 | -0.01 | |
| Capex to depreciation | 1.09 | -0.43 | -0.44 | -0.43 | -14 | |
| Stock based compensation to revenue | 0.01 | 0.03 | 0.06 | 0.1 | 0.04 | |
| Graham number | 5.31 | 3.79 | 16.91 | 10.29 | 16.52 | |
| ROIC | 0.02 | -0.01 | 0.03 | -0.04 | 0.12 | |
| Return on tangible assets | 0.05 | -0.02 | -0.51 | -0.24 | 0.63 | |
| Graham Net | 1.21 | -0.05 | 0.2 | -1.21 | -1.48 | |
| Working capital | 817.5M | 654.6M | 687.8M | 368.8M | 306.1M | |
| Tangible asset value | 70.9M | 209.3M | 264.7M | 63M | 32.4M | |
| Net current asset value | 366.6M | 100.4M | 153.4M | -84.6M | -127M | |
| Invested capital | 0.3 | 0.31 | 0.45 | 0.55 | 0.58 | |
| Average receivables | 240.5M | 285.2M | 371.85M | 319.3M | 215.55M | |
| Average payables | 71.55M | 71.6M | 6.05M | 5.45M | 7M | |
| Average inventory | 0 | 0 | 0 | 0 | 60.05M | |
| Days sales outstanding | 107.76 | 146.83 | 142.75 | 159.72 | 81.13 | |
| Days payables outstanding | 40.6 | 5.11 | 3.95 | 3.87 | 10.45 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 144.31 | |
| Receivables turnover | 0.84 | 0.61 | 0.63 | 0.56 | 1.11 | |
| Payables turnover | 2.22 | 17.62 | 22.8 | 23.26 | 8.61 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0.62 | |
| ROE | 0.03 | -0.01 | -0.61 | -0.34 | 0.96 | |
| Capex per share | 0.12 | -0.05 | -0.05 | -0.04 | -0.02 |
SGFY Frequently Asked Questions
What is Signify Health, Inc. stock symbol ?
Signify Health, Inc. is a US stock , located in Dallas of Tx and trading under the symbol SGFY
What is Signify Health, Inc. stock quote today ?
Signify Health, Inc. stock price is $- today.
Is Signify Health, Inc. stock public?
Yes, Signify Health, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.65M
- Market Capitalization 8.93B
- Employee 2.1K
- CEO Mr. Bradford Kyle Armbrester
- Headquarters Dallas,TX,US
- IPO Date 2021-02-11
-
Website
https://www.signifyhealth.com 
Signify Health, Inc. operates a healthcare platform that utilizes analytics, technology, and healthcare provider networks in the United States. The company operates through Home & Community Services and Episodes of Care Services segments. The Home & Community Services segment offers health evaluations performed within the patient's home or at a healthcare provider facility primarily to Medicare Advantage health plans; diagnostic screening and other ancillary services; and services to address healthcare concerns related to social determinants of health. The Episodes of Care Services segment provides services to enhance the healthcare delivery through developing and managing episodic payment programs in partnership with healthcare providers under the Bundled Payment for Care Improvement Advanced program with Centers for Medicare and Medicaid Services; and care management services. The company serves health plans, governments, employers, health systems, and physician groups. The company operates in Norwalk, Connecticut, New York, New York, Dallas, Texas, South Dakota, Deerfield, Florida, and Rapid City. Signify Health, Inc. was founded in 2017 and is headquartered in Dallas, Texas.
